1 1 Carnbo Clinical Research Limited SC233121 false 2023-07-01 2024-06-30 2024-06-30 The principal activity of the company is biological research. Digita Accounts Production Advanced 6.30.9574.0 true SC233121 2023-07-01 2024-06-30 SC233121 2024-06-30 SC233121 bus:OrdinaryShareClass1 2024-06-30 SC233121 core:CurrentFinancialInstruments 2024-06-30 SC233121 core:CurrentFinancialInstruments core:WithinOneYear 2024-06-30 SC233121 core:FurnitureFittingsToolsEquipment 2024-06-30 SC233121 core:LandBuildings 2024-06-30 SC233121 core:OtherPropertyPlantEquipment 2024-06-30 SC233121 bus:SmallEntities 2023-07-01 2024-06-30 SC233121 bus:AuditExemptWithAccountantsReport 2023-07-01 2024-06-30 SC233121 bus:FilletedAccounts 2023-07-01 2024-06-30 SC233121 bus:SmallCompaniesRegimeForAccounts 2023-07-01 2024-06-30 SC233121 bus:RegisteredOffice 2023-07-01 2024-06-30 SC233121 bus:CompanySecretary1 2023-07-01 2024-06-30 SC233121 bus:Director1 2023-07-01 2024-06-30 SC233121 bus:OrdinaryShareClass1 2023-07-01 2024-06-30 SC233121 bus:PrivateLimitedCompanyLtd 2023-07-01 2024-06-30 SC233121 bus:Agent1 2023-07-01 2024-06-30 SC233121 core:FurnitureFittings 2023-07-01 2024-06-30 SC233121 core:FurnitureFittingsToolsEquipment 2023-07-01 2024-06-30 SC233121 core:LandBuildings 2023-07-01 2024-06-30 SC233121 core:OfficeEquipment 2023-07-01 2024-06-30 SC233121 core:OtherPropertyPlantEquipment 2023-07-01 2024-06-30 SC233121 countries:Scotland 2023-07-01 2024-06-30 SC233121 2023-06-30 SC233121 core:FurnitureFittingsToolsEquipment 2023-06-30 SC233121 core:LandBuildings 2023-06-30 SC233121 core:OtherPropertyPlantEquipment 2023-06-30 SC233121 2022-07-01 2023-06-30 SC233121 2023-06-30 SC233121 bus:OrdinaryShareClass1 2023-06-30 SC233121 core:CurrentFinancialInstruments 2023-06-30 SC233121 core:CurrentFinancialInstruments core:WithinOneYear 2023-06-30 SC233121 core:FurnitureFittingsToolsEquipment 2023-06-30 SC233121 core:LandBuildings 2023-06-30 SC233121 core:OtherPropertyPlantEquipment 2023-06-30 xbrli:pure iso4217:GBP xbrli:shares

Registration number: SC233121

Carnbo Clinical Research Limited

Unaudited Filleted Financial Statements

for the Year Ended 30 June 2024

 

Carnbo Clinical Research Limited

Contents

Company Information

1

Balance Sheet

2

Notes to the Unaudited Financial Statements

3 to 6

 

Carnbo Clinical Research Limited

Company Information

Director

Mrs C Macdonald

Company secretary

Mr A MacDonald

Registered office

Bleachfield Mill
By Auchtermuchty
Fife
KY14 7EF

Accountants

Ross McConnell
Chartered Accountant3 High Street
Kinross
KY13 8AW

 

Carnbo Clinical Research Limited

(Registration number: SC233121)
Balance Sheet as at 30 June 2024

Note

2024
£

2023
£

Fixed Assets

 

Tangible Assets

4

-

187,261

Current assets

 

Debtors

-

962

Cash at bank and in hand

 

98,763

96,233

 

98,763

97,195

Creditors: Amounts falling due within one year

5

(2,427)

(2,427)

Net current assets

 

96,336

94,768

Net assets

 

96,336

282,029

Capital and reserves

 

Called up share capital

6

1

1

Retained earnings

96,335

282,028

Shareholders' funds

 

96,336

282,029

For the financial year ending 30 June 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the director has not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the director on 25 March 2025
 

.........................................
Mrs C Macdonald
Director

 

Carnbo Clinical Research Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 June 2024

1

General information

The company is a private company limited by share capital, incorporated in Scotland.

The address of its registered office is:
Bleachfield Mill
By Auchtermuchty
Fife
KY14 7EF

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the provision of services in the ordinary course of the company’s activities.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tangible Assets

Tangible Assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

 

Carnbo Clinical Research Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 June 2024

Asset class

Depreciation method and rate

Office Equipment

25% straight line

Fixtures & Fittings

25% straight line

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

3

Staff numbers

The average number of persons employed by the company (including the director) during the year, was 1 (2023 - 1).

 

Carnbo Clinical Research Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 June 2024

4

Tangible Assets

Land and buildings
£

Fixtures & Fittings
 £

Office Equipment
 £

Total
£

Cost or valuation

At 1 July 2023

187,000

3,980

7,861

198,841

Disposals

(187,000)

-

-

(187,000)

At 30 June 2024

-

3,980

7,861

11,841

Depreciation

At 1 July 2023

-

3,980

7,600

11,580

Charge for the year

-

-

261

261

At 30 June 2024

-

3,980

7,861

11,841

Carrying amount

At 30 June 2024

-

-

-

-

At 30 June 2023

187,000

-

261

187,261


 

5

Creditors

Creditors: amounts falling due within one year

2024
£

2023
£

Due within one year

Accruals and deferred income

470

470

Other creditors

1,957

1,957

2,427

2,427

 

Carnbo Clinical Research Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 June 2024

6

Share capital

Allotted, called up and fully paid shares

2024

2023

No.

£

No.

£

Ordinary shares of £1 each

1

1

1

1